Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s Ventana bid advances in court

This article was originally published in The Gray Sheet

Executive Summary

Ventana Medical Systems is preliminarily enjoined from using certain anti-takeover provisions to avert Roche's $3 billion hostile bid for the Tucson-based cancer diagnostics firm under an Arizona federal district court decision Aug. 21. Swiss firm Roche launched its $75-per-share tender offer for Ventana June 27, and has extended the offer's expiration date from Aug. 23 to Sept. 20. The offer represents a 44% premium over Ventana's last stock closing price before the bid was announced, although the market price has since soared as high as $88. Ventana says it remains "steadfast" in its belief that Roche's bid is "wholly inadequate" (1"The Gray Sheet" July 2, 2007, p. 10)...
Advertisement

Related Content

Roche extends hostile bid for Ventana
Ventana snaps up Spring Bioscience
Roche Seeks Diagnostics To Pair With Cancer Drugs In $3 Billion Ventana Bid
Roche Seeks Diagnostics To Pair With Cancer Drugs In $3 Billion Ventana Bid
Advertisement
UsernamePublicRestriction

Register

MT025188

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel